Abstract:The emergence and re-emergence of pathogens with pandemic potential has been a persistent issue throughout history. Recent decades have seen significant outbreaks of zoonotic viruses from members of the Coronaviridae, Filoviridae, Paramyxoviridae, Flaviviridae, and Togaviridae families, resulting in widespread infections. The continual emergence of zoonotic viral pathogens and associated infections highlights the need for prevention strategies and effective treatments. Central to this effort is the availability of suitable animal models, which are essential for understanding pathogenesis and assessing transmission dynamics. These animals are also critical for evaluating the safety and efficacy of novel vaccines or therapeutics and are essential in facilitating regulatory approval of new products. Rapid development of animal models is an integral aspect of pandemic response and preparedness; however, their establishment is fraught by several rate-limiting steps, including selection of a suitable species, the logistical challenges associated with sharing and disseminating transgenic animals (e.g., the time-intensive nature of breeding and maintaining colonies), the availability of technical expertise, as well as ethical and regulatory approvals. A method for the rapid development of relevant animal models that has recently gained traction, in large part due to the COVID-19 pandemic, is the use of gene therapy vectors to express human viral receptors in readily accessible laboratory animals to enable virus infection and development of clinical disease. These models can be developed rapidly on any genetic background, making mechanistic studies and accelerated evaluation of novel countermeasures possible. In this review, we will discuss important considerations for the effective development of animal models using viral vector approaches and review the current vector-based animal models for studying viral pathogenesis and evaluating prophylactic and therapeutic strategies, with an emphasis on models of SARS-CoV-2 infection based on the vectorized expression of human angiotensin-converting enzyme 2.

Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective

Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects

Advances in Post-Pandemic Viral Antigen Production for Vaccines

Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles

HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors

Application of Traditional Vaccine Development Strategies to SARS-CoV-2

Engineering Antiviral Vaccines

Bacterial Membrane Vesicles as a Novel Vaccine Platform against SARS-CoV-2

The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2

Cell culture-based influenza vaccines: A necessary and indispensable investment for the future

Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections

Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review

The mRNA vaccine platform for veterinary species

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

Advances in gene-based vaccine platforms to address the COVID-19 pandemic

Innovative translational platforms for rapid developing clinical vaccines against COVID-19 and other infectious disease

Recent Advancements in Developing Animal Models for COVID-19

Production of Recombinant Viral Antigens Using the Baculovirus-Insect Cell Expression System

Rapid Development of Small Rodent Animal Models for Infectious Disease Research Through Vectorized Receptor Molecule Expression

Revolutionizing Veterinary Health with Viral Vector-Based Vaccines

Influenza Vaccine: An Engineering Vision from Virological Importance to Production